Postmortem studies on a patient with mucopolysaccharidosis type I: Histopathological findings after one year of enzyme replacement therapy

Journal of Inherited Metabolic Disease

Volumn 32, Issue SUPPL. 1, 2009, Pages

  Yano, S ^a   Moseley, K ^a   Pavlova, Z ^b  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; LEVO IDURONIDASE;

ARTICLE; AUTOPSY; CASE REPORT; ENDOCARDIUM; ENZYME REPLACEMENT; HEART FAILURE; HEART MUSCLE; HUMAN; HURLER SYNDROME; MALE; METABOLISM; PATHOLOGY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD;

AUTOPSY; CHILD, PRESCHOOL; ENDOCARDIUM; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HEART FAILURE; HUMANS; IDURONIDASE; MALE; MUCOPOLYSACCHARIDOSIS I; MYOCARDIUM; POSTOPERATIVE COMPLICATIONS;

EID: 84881002836     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-1057-4     Document Type: Article

References (9)

1. Aldenhoven M, Boelens JJ, de Koning TJ (2008) The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 14: 485-498. doi:10.1016/j.bbmt.2008.01.009. (Pubitemid 351494741)
2. Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A, et al (2006) Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in Hurler syndrome. Pediatr Res 59: 27-32. doi:10.1203/01.pdr. 0000190579.24054.39.
3. Hinek A, Wilson SE (2000) Impaired elastogenesis in Hurler disease: Dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156: 925-938. (Pubitemid 30626951)
4. Lin HY, Lin SP, Chuang CK, et al (2005) Mucopolysaccharidosis I under enzyme replacement therapy with laronidase - a mortality case with autopsy report. J Inherit Metab Dis 28: 1146-1148. doi:10.1007/s10545-005-0211-x.
5. Mohan UR, Hay AA, Cleary MA, et al (2002) Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 91: 799-804. doi:10.1080/08035250213211. (Pubitemid 34876167)
6. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, et al (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression - targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14: 846-852. doi:10.1038/sj.ejhg.5201623. (Pubitemid 43923370)
7. Sifuentes M, Doroshow R, Hoft R, et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90: 171-180. doi:10.1016/j.ymgme.2006.08.007. (Pubitemid 46108607)
8. Stephan MJ, Stevens EL Jr, Wenstrup RJ, et al (1989) Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy. Am J Dis Child 143: 782-784. (Pubitemid 19172095)
9. Wraith JE, Beck M, Lane R, et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human α-L-Iduronidase (Laronidase). Pediatrics 120: e37-46. doi:10.1542/peds.2006-2156. (Pubitemid 47036214)